Prostate cancer screening
The management of clinically localised prostate cancer diagnosed after a PSA test remains controversial. Active surveillance is an option that can help ameliorate the negative effects of over-treatment of PSA-detected prostate cancer. The longer term outcomes of this approach compared … Continue reading
Prostate cancer care has changed in recent years out of concern for over-diagnosis and over-treatment. However, many patients continue to undergo some form of curative treatment, and there is a perception among clinicians that more aggressive treatments are being favoured. … Continue reading
The Prostate Cancer Foundation of Australia and Cancer Council Australia along with input from an expert advisory panel, which included Andrology Australia’s Director Prof Rob McLachlan, have developed national evidence-based clinical practice guidelines on PSA testing and early management of … Continue reading
The doctor says it’s time for you to have a PSA test. But what is the PSA test exactly?
A recent study found that viewing a video-format decision aid reduced men’s interest in PSA screening, primarily those who were undecided prior to viewing the aid and more than half wanted to speak to their doctor about their decision.
A study recently published in the BMJ examined the question, what level of over-detection people might find acceptable in cancer screening, given the expected benefit from screening and harms from over-detection?
Andrology Australia has attempted to review and summarise the current guidelines and position statements on PSA testing.
Andrology Australia recommends that a man considering PSA testing should be informed that there are uncertainties about treatment options in prostate cancer, that there are both potential gains and risks from PSA testing, and that an abnormal PSA result must be confirmed by further testing.
Research findings show that biomarkers may help to improve prognostic models for localised prostate cancer.